Predictive value of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma

Annals of Nuclear Medicine

Volumn 27, Issue 1, 2013, Pages 1-10

  Inubushi, Masayuki ^a   Saga, Tsuneo ^a   Koizumi, Mitsuru ^a   Takagi, Ryo ^b   Hasegawa, Azusa ^b   Koto, Masashi ^b   Wakatuki, Masaru ^b   Morikawa, Takamichi ^b   Yoshikawa, Kyosan ^b   Tanimoto, Katsuyuki ^b   Fukumura, Toshimitsu ^a   Yamada, Shigeru ^b   Kamada, Tadashi ^b  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Carbon ion radiotherapy (CIRT); F18 Fluorothymidine (FLT); Head and neck neoplasms; Mucosal malignant melanoma (MMM); Positron emission tomography and computed tomography (PET CT)

Indexed keywords

3' FLUOROTHYMIDINE F 18;

AGE; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; DRUG UPTAKE; FEMALE; FOLLOW UP; GENDER; HEAD AND NECK CANCER; HUMAN; ION THERAPY; LYMPH NODE METASTASIS; MALE; MELANOMA; MUCOSAL MALIGNANT MELANOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RADIATION DOSE; SURVIVOR; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; DIDEOXYNUCLEOSIDES; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HEAVY ION RADIOTHERAPY; HUMANS; MALE; MELANOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84872685192     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0652-x     Document Type: Article

References (42)

1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664-8.
2. Japan Society of Head and Neck Cancer: Cancer Registry Committee. Report of Head and Neck Cancer Registry of Japan: clinical statistics of registered patients. Head Neck. Cancer. 2002;2006(32):3.
3. Gavriel H, McArthur G, Sizeland A, Henderson M. Review: mucosal melanoma of the head and neck. Melanoma Res. 2011;21:257-66.
4. Seetharamu N, Ott PA, Pavlick AC. Mucosal melanomas: a case-based review of the literature. Oncologist. 2010;15:772-81.
5. Prasad ML, Patel SG, Huvos AG, Shah JP, Busam KJ. Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, stage I (lymph node-negative) tumors. Cancer. 2004;100:1657-64.
6. Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer. 1997;80:1373-86.
7. Combs SE, Konkel S, Thilmann C, Debus J, Schulz-Ertner D. Local high-dose radiotherapy and sparing of normal tissue using intensity-modulated radiotherapy (IMRT) for mucosal melanoma of the nasal cavity and paranasal sinuses. Strahlenther Onkol. 2007;183:63-8.
8. Ahn HJ, Na II, Park YH, Cho SY, Lee BC, Lee GH, et al. Role of adjuvant chemotherapy in malignant mucosal melanoma of the head and neck. Oral Oncol. 2010;46:607-11.
9. Bradley PJ. Primary malignant mucosal melanoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg. 2006;14:100-4.
10. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25:953-64.
11. Okada T, Kamada T, Tsuji H, Mizoe JE, Baba M, Kato S, et al. Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS). J Radiat Res (Tokyo). 2010;51:355-64.
12. Jingu K, Kishimoto R, Mizoe JE, Hasegawa A, Bessho H, Tsuji H, et al. Malignant mucosal melanoma treated with carbon ion radiotherapy with concurrent chemotherapy: prognostic value of pretreatment apparent diffusion coefficient (ADC). Radiother Oncol. 2011;98:68-73.
13. Yanagi T, Mizoe JE, Hasegawa A, Takagi R, Bessho H, Onda T, et al. Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Radiat Oncol Biol Phys. 2009;74:15-20.
14. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-6.
15. 18F]fluorothymidine. Semin Nucl Med. 2007;37:429-39.
16. 18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-21.
17. Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol. 2011;29:1701-8.
18. Saga T, Koizumi M, Inubushi M, Yoshikawa K, Tanimoto K, Fukumura T, et al. PET/CT with 3′-deoxy-3′-[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy. Nucl Med Commun. 2011;32(5):348-55.
19. Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, Graf N, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med. 2011;52:690-6.
20. Ross MI. Early-stage melanoma: staging criteria and prognostic modeling. Clin Cancer Res. 2006;12:2312s-9s.
21. Kim DK, Kim DW, Kim SW, Kim DY, Lee CH, Rhee CS. Ki67 antigen as a predictive factor for prognosis of sinonasal mucosal melanoma. Clin Exp Otorhinolaryngol. 2008;1:206-10.
22. Kanai T, Matsufuji N, Miyamoto T, Mizoe J, Kamada T, Tsuji H, et al. Examination of GyE system for HIMAC carbon therapy. Int J Radiat Oncol Biol Phys. 2006;64:650-6.
23. Mizoe JE, Hasegawa A, Jingu K, Takagi R, Bessyo H, Morikawa T, et al. Results of carbon ion radiotherapy for head and neck cancer. Radiother Oncol. 2012;103:32-7.
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
25. 18F]FLT. Nucl Med Biol. 2002;29:263-73.
26. Koizumi M, Saga T, Yoshikawa K, Baba M. Gastric cancer found on 3′-deoxy-3′ F-18 fluorothymidine positron emission tomography. Clin Nucl Med. 2008;33:641-2.
27. Koizumi M, Saga T, Inubushi M, Fukumura T, Yoshikawa K, Yamamoto N, et al. Uptake decrease of proliferative PET tracer 18FLT in bone marrow after carbon ion therapy in lung cancer. Mol Imaging Biol. 2011;13:577-82.
28. Woodard HQ, Bigler RE, Freed B. Expression of tissue isotope distribution. J Nucl Med. 1975;16:958-9.
29. Prasad ML, Busam KJ, Patel SG, Hoshaw-Woodard S, Shah JP, Huvos AG. Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract. Arch Pathol Lab Med. 2003;127:997-1002.
30. McLean N, Tighiouart M, Muller S. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma. Oral Oncol. 2008;44:1039-46.
31. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-8.
32. Friedman RJ, Rigel DS, Kopf AW, Grin CM, Heilman E, Bart RS, et al. Volume of malignant melanoma is superior to thickness as a prognostic indicator. Preliminary observation. Dermatol Clin. 1991;9:643-8.
33. Jethanamest D, Vila PM, Sikora AG, Morris LG. Predictors of survival in mucosal melanoma of the head and neck. Ann Surg Oncol. 2011;18:2748-56.
34. Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L, et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57:953-62.
35. Barwick T, Bencherif B, Mountz JM, Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun. 2009;30:908-17.
36. Shields AF. PET imaging of tumor growth: not as easy as it looks. Clin Cancer Res. 2012;18:1189-91.
37. Bachar G, Loh KS, O'Sullivan B, Goldstein D, Wood S, Brown D, et al. Mucosal melanomas of the head and neck: experience of the Princess Margaret Hospital. Head Neck. 2008;30:1325-31.
38. Kim HS, Kim EK, Jun HJ, Oh SY, Park KW, do Lim H, et al. Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer. 2010;10:167.
39. Nandapalan V, Roland NJ, Helliwell TR, Williams EM, Hamilton JW, Jones AS. Mucosal melanoma of the head and neck. Clin Otolaryngol Allied Sci. 1998;23:107-16.
40. Weksler ME, Tsuda T, Ershler W, Kim YT, Siskind GW, Esposito D, et al. Immune senescence contributes to the slow growth of tumors in elderly subjects. Ann N Y Acad Sci. 1988;521:177-81.
41. Patel SG, Prasad ML, Escrig M, Singh B, Shaha AR, Kraus DH. Primary mucosal malignant melanoma of the head and neck. Head Neck. 2002;24:247-57.
42. Medina JE, Ferlito A, Pellitteri PK, Shaha AR, Khafif A, Devaney KO, et al. Current management of mucosal melanoma of the head and neck. J Surg Oncol. 2003;83:116-22.